LAWRENCE, Mass., Oct. 31 /PRNewswire-FirstCall/ -- NxStage Medical, Inc. today announced that the underwriters of its recent initial public offering have exercised their over-allotment option to purchase an additional 825,000 shares of common stock at the public offering price of $10.00 per share. Upon closing of the offering, a total of 6,325,000 shares of common stock will have been sold, resulting in gross proceeds of $63.2 million and net proceeds of $57.1 million, after payment of underwriting discounts and commissions and estimated offering expenses. Merrill Lynch & Co. was the book runner for the offering with Thomas Weisel Partners, LLC, William Blair and Company and JMP Securities acting as co-managers.
Copies of the final prospectus relating to the offering may be obtained by contacting Merrill Lynch & Co., 4 World Financial Center, New York, New York 10080 USA (telephone: +1.212.449.1000).
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on October 27, 2005. The public offering is being made by means of a written prospectus forming part of the effective registration statement. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About NxStage Medical
NxStage Medical, Inc. is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative systems for the treatment of end-stage renal disease, or ESRD, and acute kidney failure.
NxStage Medical, Inc.
CONTACT: David N. Gill, Senior Vice President & Chief Financial Officer ofNxStage Medical, Inc., +1-978-687-4700
Web site: http://www.nxstage.com//
